Abstract
To the Editor: We thank Dr. Ranganathan for her interesting comments1 on our work2. In our recently published prediction model for methotrexate (MTX) non-response in juvenile idiopathic arthritis (JIA)3, ABCB1 rs1045642 was described, indicating the relative importance of this polymorphism to predict nonresponse to MTX in JIA. Also, we were able to reproduce this finding in a prospective cohort of 387 adult patients with rheumatoid arthritis (RA) receiving MTX: the ABCB1 rs1045642 polymorphism showed an association with improved clinical response (lower Disease Activity Score-28; ß = −0.16, p = 0.001). We agree that finding genetic predictors for MTX-induced toxicity and gastrointestinal (GI) adverse events is equally as important as response, because toxicity limits the considerations of a dose increase or continuation of MTX, and … Address correspondence to R. de Jonge, Department of Clinical Chemistry, Erasmus MC, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. E-mail: r.dejonge{at}erasmusmc.nl
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call